SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The mission of the Worldcoin project is to build the world’s largest identity and financial network as a public utility, giving ownership to everyone. A key component of the Worldcoin project is the development of the foundational infrastructure that will be important for a world where AI plays an increasingly large role.  The Worldcoin system revolves around World ID, a privacy-preserving global identity network. World ID enables users to verify their humanness online while maintaining their privacy through zero-knowledge proofs.  Using World ID, individuals will be able to prove that they are a real, unique human to any platform that integrates with the protocol, including to web3 systems, social networking sites, and governmental programs. This will enable fair airdrops or token/NFT sales, provide protection against bots/sybil attacks on social media, and enable the fairer distribution of limited governmental resources. Furthermore, World ID can also enable global democratic processes and novel forms of governance (e.g., via quadratic voting), and it may eventually show a path to AI-funded UBI. The Worldcoin token (WLD), alongside World ID, will let users participate in governing the Worldcoin protocol.   To engage with the Worldcoin protocol, individuals must first download a first wallet app that supports the creation of a World ID. Users visit a physical imaging device called the Orb to get their World ID Orb-verified. Orbs are operated by a network of independent local businesses called Orb Operators. The Orb uses multispectral sensors to verify humanness and uniqueness to issue an Orb-verified World ID, with all images being promptly deleted on-device per default (absent explicit consent to Data Custody). All Orb-verified World IDs holders are entitled to claim recurring grants of free WLD tokens, subject to certain availability restrictions. The WLD token is designed as a utility token with governance properties.

Worldcoin

Worldcoin is experiencing intense community focus as traders debate its role in the "proof-of-personhood" narrative, further fueled by news of significant treasury initiatives and acquisitions by companies like Eightco Holdings and Maison Solutions. While some investors view the token as a long-term play backed by Sam Altman's AI ecosystem, others express caution regarding its high token supply and potential for volatility.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is seeing increased community activity surrounding the upcoming Goliath mainnet launch and ongoing accumulation by large whale wallets. Investors are actively debating potential price movements, with many highlighting the project's infrastructure developments while some express frustration over persistent price volatility and skepticism regarding marketing transparency.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund (USO) is surging as geopolitical instability in the Middle East intensifies following reports of strikes on major energy infrastructure, fueling intense speculation over potential global supply disruptions. Investors are closely monitoring the security of the Strait of Hormuz, with widespread community debate centered on whether escalating military involvement will exacerbate price volatility or if diplomatic off-ramps can successfully stabilize energy flows.

Dogelon Mars

Dogelon Mars is seeing renewed community buzz as investors debate the potential of this veteran meme coin to re-emerge during the current market cycle. While sentiment remains sharply divided between long-term holders hopeful for a resurgence and critics labeling it a stagnant asset, the community continues to fixate on the token's historical branding and the speculative possibility of a turnaround.

Korro Bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of a new class of genetic medicines based on editing RNA. The company was founded by Nessan Bermingham, Jean-Francois B. Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

Korro Bio Inc.

Korro Bio Inc

Korro Bio is experiencing a significant surge in trading volume and investor attention following an oversubscribed private placement of common stock and pre-funded warrants. The community is actively debating the company's financial liquidity, potential for an acquisition play, and clinical development prospects, with mixed sentiment ranging from skepticism over the company's long-term viability to bullish outlooks fueled by analyst upgrades and momentum.

BJ's Wholesale Club Holdings, Inc. engages in the operation of membership warehouse clubs. Its product categories include grocery, household and pet, television and electronics, furniture, computer and tablets, patio and outdoor living, lawn and garden, baby and kids, toys, home, health and beauty, appliances, and jewelry. The company was founded in 1984 and is headquartered in Marlborough, MA.

BJ`s Wholesale Club Holdings Inc

BJ's Wholesale Club Holdings Inc

BJ's Wholesale Club is currently in focus as investors await earnings results, with community chatter centered on comparing its membership value and store traffic to peers like Costco and Walmart. The conversation is largely driven by anticipation of whether the warehouse retailer can deliver a strong fiscal outlook despite broader retail sector headwinds and margin pressure.

Monad is a high-performance Layer 1 blockchain that processes 10,000 transactions per second with near-zero fees. The platform delivers high performance without compromising on security or decentralization, creating the infrastructure needed for complex applications that require high-frequency activity.  One of Monad’s key innovations lies in how it handles transaction processing. Instead of processing transactions one at a time like traditional blockchains, Monad processes multiple transactions simultaneously through parallel execution.   The system separates the agreement process from the execution process, allowing validators to first agree on which transactions to include and in what order, then having more time to execute those transactions without slowing down consensus. This approach, combined with a custom-built database called MonadDB, dramatically increases throughput while maintaining accuracy.  Monad also offers complete EVM compatibility, where applications built for Ethereum work on Monad without any code modifications, and users can connect with familiar wallets like MetaMask just as they would on Ethereum. Developers can immediately tap into Ethereum's established ecosystem of tools, libraries, and applications while benefitting from Monad’s performance improvements. The platform also runs on consumer-grade hardware rather than expensive specialized equipment, making it accessible for more people to participate in securing the network.  Monad has raised approximately 244 million dollars in total funding across multiple rounds. The company secured 19 million dollars in a seed round in February 2023 led by Dragonfly Capital, followed by a 225 million dollar Series A round in April 2024 led by Paradigm at a 3 billion dollar valuation. Other notable investors include Electric Capital, Greenoaks, Coinbase Ventures, and prominent angel investors such as Naval Ravikant.

Monad

Monad is generating significant buzz as traders actively monitor its technical potential as an EVM-compatible layer-1 chain, with many community members focused on long-term staking rewards as a hedge against current market volatility. While some participants express frustration over price consolidation and Coinbase's platform limitations, the bullish sentiment remains strong among those viewing the project as a foundational play for future ecosystem growth.

ETF Series Solutions - Defiance Quantum ETF

Defiance Quantum ETF

QTUM is trending as investors aggressively debate the long-term potential of the quantum computing sector, balancing excitement over high-growth breakthroughs against concerns regarding volatility and uncertain monetization timelines. Community sentiment is deeply divided, with many traders favoring the ETF as a diversified 'basket' approach to mitigate the risks inherent in betting on individual, speculative quantum stocks.

iShares Ethereum Trust (The) - Undivided Beneficial Interest

iShares Ethereum Trust ETF

Investors are actively debating the current consolidation phase of the iShares Ethereum Trust ETF (ETHA), with many using the recent price dips as an accumulation zone in anticipation of future institutional staking approvals and broader tokenization trends. While some community members remain cautious about short-term volatility and sector-wide regulatory uncertainty, the prevailing sentiment is focused on long-term accumulation as they look past current price swings toward potential milestones in the Ethereum ecosystem.

Dollar Tree, Inc. owns and operates discount variety stores offering merchandise at fixed prices. It operates through the Dollar Tree business segment. The Dollar Tree segment includes operations under Dollar Tree and Dollar Tree Canada brands, with its distribution centers in the United States and Canada. The company was founded by J. Douglas Perry and Macon F. Brock, Jr. in 1953 and is headquartered in Chesapeake, VA.

Dollar Tree Inc

Dollar Tree is trending as investors react to a significant earnings beat and raised full-year guidance, even as management warns of tariff-related headwinds and potential short-term margin pressure. The community remains focused on the company's successful multi-price strategy, which is driving traffic from higher-income shoppers, while active traders continue to debate the stock's volatility following the mixed outlook for the upcoming quarter.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$CADL Will the FDA allow a regulatory filing based on the existing data? Could CADL move toward approval for CAN-2409 (Prostate) without another large Phase 3 trial? Discuss. 

I believe the FDA will not require further trials. 

That will dramatically shorten the timeline and lower the cash burn.

Where are all these Bearish posts coming from?

Shadow Bull

Clay

EzE Trading

Cenerentola

LeverUp19

Todd Luttenegger

Robert Dobosz

Felix Hantel

Willie

Jimmy D

Luis Manuel Pena Cañizares

Greyhound9

Gregory Smock

khpower

StockTwits for iOS

Candel Therapeutics Inc

 Will the FDA allow a regulatory filing based on the existing data? Could CADL move toward approval for CAN-2409 (Prostate) without another large Phase 3 trial? Discuss. 

I believe the FDA will not require further trials. 

That will dramatically shorten the timeline and lower the cash burn.

Where are all these Bearish posts coming from?

Diggs

@PatSoonDiggler The bearish posts here are mostly the usual stock-board playbook: bashers, sentiment manipulators, and people making personal attacks with no understanding of biotech development or long-term value creation.
Biotech value is created through clinical data, regulatory dialogue with FDA, and patient outcomes, not anonymous message board noise.
The actual question worth discussing is the one you raised: whether the existing Phase 3 data could support a regulatory filing pathway. Everything else here is mostly just distraction.

Paul Nipkow

Phill

Victoria Space

Jasper Dolphin

$CADL you forgot to mention value creation hinges on good management 

Something cadl lacks. Great data, poor management 🤷‍♀️

StockTwits For Android 

broke

 The bearish posts here are mostly the usual stock-board playbook: bashers, sentiment manipulators, and people making personal attacks with no understanding of biotech development or long-term value creation.
Biotech value is created through clinical data, regulatory dialogue with FDA, and patient outcomes, not anonymous message board noise.
The actual question worth discussing is the one you raised: whether the existing Phase 3 data could support a regulatory filing pathway. Everything else here is mostly just distraction.

@PatSoonDiggler I&#39;m long and hopeful. I was disappointed that they shelved the really promising pancreatic cancer application testing for now, but I figure they see that costing a lost more in testing trials before FDA acceptable data levels. So they are focusing on their best bests for profitability in the shortest time possible and I can&#39;t blame them for that. The bears here are just impatient flippers IMO.

Noodles

StockTwits Web

 I'm long and hopeful. I was disappointed that they shelved the really promising pancreatic cancer application testing for now, but I figure they see that costing a lost more in testing trials before FDA acceptable data levels. So they are focusing on their best bests for profitability in the shortest time possible and I can't blame them for that. The bears here are just impatient flippers IMO.

@PatSoonDiggler @ShadowBull3745 out of curiosity what makes you concerned if additional data would be required…don’t Tak say the SPA was reconfirmed and they were on track for submission?

 out of curiosity what makes you concerned if additional data would be required…don’t Tak say the SPA was reconfirmed and they were on track for submission?

John smith

@HMP1716 @ShadowBull3745 

I share your view. I don’t think confirmatory trials will be required, especially given Makary’s PR regarding speedier approvals. ￼

 

I share your view. I don’t think confirmatory trials will be required, especially given Makary’s PR regarding speedier approvals. ￼

@PatSoonDiggler @ShadowBull3745 Still looking for a licensing deal this year.  Any thoughts from Turd on the public offering?

 Still looking for a licensing deal this year.  Any thoughts from Turd on the public offering?

@PatSoonDiggler They got RMAT after the trial and this type of trial takes like 7-8 years so… would be insane

M Dri

 They got RMAT after the trial and this type of trial takes like 7-8 years so… would be insane

@PatSoonDiggler can you provide one solid example FDA has ever asked for a second large phase 3 trial in any oncology setting? Probably none, could be wrong

John Albrecht

 can you provide one solid example FDA has ever asked for a second large phase 3 trial in any oncology setting? Probably none, could be wrong

@badprecog I agree. I regret posting that. I looked into it further and the chances of FDA requiring confirmatory trials for CAN-2409 are virtually NIL. (TY Turd). 

The FDA typically asks for a confirmatory Phase 3 trial when a drug receives Accelerated Approval based on a surrogate endpoint (for example tumor response rate).
 • Accelerated approval = early approval before Phase 3 proof
 • Confirmatory trial = required later to confirm benefit

If CAN-2409 already has a completed randomized Phase 3 trial demonstrating clinical benefit (for example improved survival or meaningful progression endpoints), then that Phase 3 itself serves as the confirmatory study.

So requiring another Phase 3 after a successful Phase 3 would be unusual unless:
 • The endpoint was weak
 • The trial design had major flaws
 • The benefit was marginal or inconsistent

None of those are applicable issues with CAN-2409.

I take it BACK. Diggs is sorry for throwing out stupid shit. 

LFG!!

Steven Craig

 I agree. I regret posting that. I looked into it further and the chances of FDA requiring confirmatory trials for CAN-2409 are virtually NIL. (TY Turd). 

The FDA typically asks for a confirmatory Phase 3 trial when a drug receives Accelerated Approval based on a surrogate endpoint (for example tumor response rate).
 • Accelerated approval = early approval before Phase 3 proof
 • Confirmatory trial = required later to confirm benefit

If CAN-2409 already has a completed randomized Phase 3 trial demonstrating clinical benefit (for example improved survival or meaningful progression endpoints), then that Phase 3 itself serves as the confirmatory study.

So requiring another Phase 3 after a successful Phase 3 would be unusual unless:
 • The endpoint was weak
 • The trial design had major flaws
 • The benefit was marginal or inconsistent

None of those are applicable issues with CAN-2409.

I take it BACK. Diggs is sorry for throwing out stupid shit. 

LFG!!